Lipidio

Lipidio Pharmaceuticals is a San Diego-based biopharmaceutical company founded in 2020 that acquires and develops molecules with unrealized therapeutic potential, applying its team's drug development expertise to optimize preclinical and clinical plans through to marketing approval or exit. The company is focused on two distinct indications: obesity and sebaceous hyperplasia, with a lead candidate that uses skin signaling mechanisms to deliver systemic metabolic benefits including significant weight reduction. Lipidio has raised over $20 million in Series A financing and has received support from the Foundation for Prader-Willi Research for its GDD3898 therapeutic candidate.